Dr Sandra Grumelli | The Importance of the Choline in Chronic Lung Infections

Jun 24, 2025 | Education & Training, Medical & Health Sciences

Article written by Helen Rickard, PhD

People with chronic lung conditions like COPD and cystic fibrosis are vulnerable to lung infections caused by the bacterium Pseudomonas aeruginosa. These infections are often difficult to treat and can cause sudden worsening of symptoms, known as flare-ups or acute exacerbations. While we know P. aeruginosa triggers inflammation and damage in the lungs, much less is understood about how exactly it causes these flare-ups, or how it survives in such a harsh environment. Dr Sandra Grumelli from the Center of Investigations of Respiratory Diseases in Argentina, has explored the role of a common molecule called choline which is released during infection. Using a combination of mouse models and laboratory experiments, she has discovered that choline not only makes breathing harder, it also helps P. aeruginosa adapt to and persist in the lungs. Her research opens up new possibilities for tackling chronic infections by targeting the bacteria’s energy use and the way it responds to its environment.

 Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (commonly known as COPD) is the name for a group of lung conditions that cause breathing difficulties. These conditions include emphysema, where the air sacs in the lungs called alveoli disappear. The walls in these sacs are usually stretchy, allowing them to fill with air. In people with COPD, it is harder for these sacs to inflate and deflate, causing difficulties with breathing. Another aspect of COPD is chronic bronchitis, when the lining of the airway becomes irritated and inflamed, leading to cough and overproduction of mucus.

In the United States COPD affects more than 14 million people and is the sixth leading cause of death, according to the Centers for Disease Control and Prevention. The most common COPD symptoms are shortness of breath, a persistent cough, and feeling very tired. COPD symptoms can suddenly get worse for a few days, known as flare ups or acute exacerbation which often need additional treatment. COPD happens when the lungs become damaged and inflamed often due to smoking, air pollution, or a genetic mutation. There is currently no cure or way to reverse COPD damage to the lungs because the air sacs disappear, but steroids and oxygen can help people through flare-ups.

During flare ups people may cough more, produce more mucus, struggle to breathe, and have to breathe faster to get enough oxygen. Normally the physical process of breathing uses only a little bit of the body’s oxygen (about 5%), but during a flare up it can take a lot more effort (up to 250%) and oxygen just to keep breathing. This is partly because during a flare up there is more tissue resistance and the lungs can’t breathe out carbon dioxide properly, causing it to build up the blood in a process called hypercapnia which makes the blood more acidic. 

Cystic Fibrosis

Another condition which can lead to breathing difficulties, persistent coughs, and frequent lung infections is cystic fibrosis. This is a genetic condition, where a faulty gene is passed down by both parents, resulting in the production of thick mucus which affects the lungs and other body systems. Cystic fibrosis also currently has no cure, but similarly to COPD, treatments including steroids and inhaled medicines which widen the airways can improve respiratory symptoms.

Pseudomonas aeruginosa and Lung Diseases

Both COPD and cystic fibrosis make people more vulnerable to bacterial infections of the lungs and respiratory tract. A key bacterial species which can cause these infections is Pseudomonas aeruginosa (P. aeruginosa), this bacterium can cause infections in all parts of the body including the skin and gut but is notorious for causing hard to treat infections in people with underlying respiratory conditions.

Up to 20% of people diagnosed with COPD are infected with P. aeruginosa, and P. aeruginosa is the leading cause of lung infections in people with cystic fibrosis. Infection by P. aeruginosa in people with lung conditions can lead to a decline in lung function, increased symptom flare ups, and is associated with worse clinical outcomes and reduced lifespan. P. aeruginosa is able to release harmful substance within the lungs and respiratory tract during infections. The outer surface of the P. aeruginosa bacteria includes molecules called lipopolysaccharide or LPS, these trigger our immune system leading our body to release inflammatory molecules and enzymes which can further damage lung tissues and contribute to worsening of respiratory symptoms. 

Despite being so hard to treat and a major caused of illness, little is known about how P. aeruginosa causes severe lung disease acute exacerbation. Dr Sandra Grumelli has led a team of expert researchers at the CIMeR in Argentina alongside scientists at Harvard Medical School to understand the molecular mechanisms between P. aeruginosa and lung disease symptoms.

Choline

The Importance of Choline

Choline is a naturally occurring molecule found in the membranes around cells and in surfactant, the slippery substance which helps keep our lungs open. As well as its LPS triggering the immune system, P. aeruginosa can also produce enzymes which break down the lung surfactant, as this breaks down it releases a molecule called choline. Choline can trigger the airways to narrow and change how blood vessels within the lungs behave, making breathing even harder.

Dr Grumelli and her team at Harvard Medical School conducted a series of experiments to find out if the production of choline by P. aeruginosa may actually be triggering the flare ups. The team used a mouse model to understand the role of P. aeruginosa in the development of respiratory flare up symptoms. First, they exposed some of the mice to cigarette smoke over time to create emphysema-like lung damage, they then added LPS from P. aeruginosa to mimic the lung inflammation that would be seen during infection to some of the mice. Choline was then given and the team conducted experiments to see how these factors affected the mouse lungs. They used a specialised machine to measure how hard the lungs had to work to breathe, including checking lung stiffness, resistance in the airways, and how much oxygen and carbon dioxide the mice were breathing in and out. They also collected lung fluid samples to count the immune cells, and looked at lung tissue under a microscope to check for damage. They measured how much energy the mice were using and how the levels of carbon dioxide and acidity in their blood changed.

The team also wanted to understand how choline impacts P. aeruginosa, so in laboratory experiments they grew the bacteria using choline and a different molecule called succinate as its food source. They then assessed the levels of key molecules within the bacterial cells and speculated how this might impact the bacteria’s behaviour within the human lung.

Dr Grumelli found that the LPS caused a strong immune reaction in the lungs, with high numbers of inflammatory cells that released enzymes and damaged tissues, this led to the breakdown of the alveoli and made the lungs less elastic. They also discovered that choline made breathing much harder, the lungs had to use more energy and oxygen to function causing carbon dioxide to build up and acidify the blood. Interestingly, the team also found that choline doesn’t just affect the lungs it also changes the bacteria, exposure to choline caused P. aeruginosa in the lab test to produce more LPS which would allow it to stick to and damage lung tissues. It also caused the bacteria to reduce its energy needs giving it a survival advantage in the lung.

Polyphosphate Production

These findings suggested that treating people with P. aeruginosa lung infections with succinate, may reduce the symptoms associate with choline and make the infections easier to treat. To understand more about how choline impacts P. aeruginosa in lung infections the team in Argentina expanded on their previous experiments and grew the bacteria in the lab using choline as its main energy source and compared it to bacteria grown with succinate.

Dr Grumelli discovered that choline caused the bacteria to switch into a survival mode, building up large amounts of a compound called polyphosphate which helps bacteria handle stress, resist attack by the body’s immune systems, and be able to persist in the lungs for longer periods of time. They also found that an enzyme called polyphosphate kinase was much more active in the choline fed bacteria, while the enzyme polyphosphate phosphatase, which breaks down the polyphosphate, became less active. This resulting in the bacteria being able to build up large stores of polyphosphates and produce more LPS.

The laboratory tests showed that the bacteria grown with choline made less energy, but this allowed them to become more efficient. As they used less oxygen, they were also more able to survive in the low oxygen environment found within damaged lungs.

Polyphosphate kinase

What This Research Could Mean for Patients

Dr Grumelli’s work provides exciting insights into why P. aeruginosa infections are so difficult to manage in people with chronic lung conditions such as COPD and cystic fibrosis. Their work reveals that choline, a molecule naturally found in our lungs, plays a surprising double role as it not only makes breathing harder for patients during flare ups, but it also helps the bacteria survive and cause more damage.

This research highlights the potential for possible new treatment strategies. For example, targeting the bacterial enzymes that respond to choline, or changing the nutrients available in the lungs could reduce the severity of infections and improve patient outcomes. Dr Grumelli’s findings may lead to therapies that go beyond antibiotics and support people living with chronic hard to treat lung infections.

SHARE

DOWNLOAD E-BOOK

REFERENCE

https://doi.org/10.33548/SCIENTIA1284

MEET THE RESEARCHER


Dr Sandra Grumelli
Centro de Investigación en Medicina (CIMeR), Universidad Católica de Córdoba, Argentina

Dr Sandra Grumelli is a biomedical scientist with over two decades of experience in respiratory research, translational science, and immunology. She obtained her PhD in Biology from the National University of Río Cuarto in Argentina, followed by extensive postdoctoral training at leading institutions including Baylor College of Medicine and Harvard Medical School. Her research has focused on chronic lung diseases, particularly the immune and metabolic interactions between Pseudomonas aeruginosa and the human host in cystic fibrosis and COPD. Dr Grumelli has held research and teaching appointments in Argentina and the USAle, led projects funded by Tufts University and the American Thoracic Society, and received multiple international fellowships and travel awards. Dr Grumelli is also a science communicator, peer reviewer for leading journals including PLOS ONE and FEMS, and currently serves as an editor for The Journal of Disease. She combines her scientific background with certified training in medical interpretation to help bridge communication in clinical and research settings.

CONTACT

E: sgrumelli@yahoo.com

KEY COLLABORATORS

Alejandro Rossi from Rizobacter

FUNDING

CONICOR 72/95, 252/96, 417/97, 1380/97

CABBIO

UNRC Res1073, Exp57803

American Thoraxic Society

National Insitute of Health

St. Elizabeth Hospital

CIMeR

FURTHER READING

S Grumelli., Choline Triggers Exacerbations of Chronic Obstructive Pulmonary Disease in Patients Infected with Pseudomonsa aeruginosa, Current Respiratory Medicine Review, 2016, 12(2) 167-174. DOI: https://doi.org/10.2174/1573398X12999160506104327

S Grumelli, A Rossi., Bioenergetics of the Polyphosphates Accumulation in Pseudomonas aeruginosa via Polyphosphate Kinase Activation by Choline in a Lung Colonization Model, Heliyon, 2023, 9(2). DOI: https://doi.org/10.1016/j.heliyon.2022.e12601

REPUBLISH OUR ARTICLES

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence (CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

SUBSCRIBE NOW


Follow Us

MORE ARTICLES YOU MAY LIKE

Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia

Assoc Prof. Nicholas Brown | Rethinking Prostate Care: A New Frontier in Treating Benign Prostatic Hyperplasia

For millions of men, ageing brings with it a set of frustrating and often disruptive urinary symptoms. These symptoms, caused by benign prostatic hyperplasia, or BPH, can affect sleep, confidence, and overall quality of life. Traditionally, treatment follows a familiar path. Patients begin with medications, often for years, and may eventually progress to surgery if symptoms worsen. Yet this pathway is not without its drawbacks. Medications can cause side effects, while surgery carries risks and recovery time. In recent years, a minimally invasive interventional radiology procedure called prostate artery embolisation, or PAE, has begun to challenge this traditional model. At the forefront of this shift is a collaborative research group, led by Dr. Nicholas Brown of the University of Queensland, whose series of P-EASY studies has explored whether PAE could transform how BPH is treated, particularly at earlier stages.

Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach

Jean Lycke | Addressing Unmet Medical Needs in Mucosal Disease: A Close-to-Market Innovation Approach

Recurrent Aphthous Stomatitis (RAS) is an oral condition characterized by one or several painful mucosal ulcers. RAS affects a large proportion of the population and has a point prevalence of approximately 2–3%, daily. The etiology remains unknown, and there is currently no curative treatment. Most patients experience recurring episodes over time, with each episode typically lasting up to a week. Here, we describe the development of a mucoadhesive patch which, when applied over a RAS ulcer, provides rapid pain relief. The patch is easy for patients to apply when symptoms begin and has the potential to be used as an over-the-counter product. The development of the Mucocort mucoadhesive patch is an example of a Close-to-Market innovation strategy that embraces simplicity within a complex healthcare system. By simplifying the product concept, the team has reduced the number of regulatory steps required before market approval. This MedTech/Pharma innovation model, known as the “4R” framework – Re-purposing, Re-formulation, Re-positioning, and Re-patenting – has guided the program from concept to commercialization. In addition to the biodegradable mucoadhesive patch developed for RAS ulcers, the team is extending the innovation concept to a mucoadhesive gel formulation for the prevention and treatment of chemotherapy-induced mucositis. This gel-based program is being commercialized separately through MucoShield.

The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

The Translational Asian Agerelated Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease headon. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.

Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep

Ms. Aikaterini Dritsoula | Looking Beyond Snoring: How Hidden Airway Problems Shape Children’s Sleep

For many parents, a child’s snoring may seem harmless, even endearing. Yet in some cases, it signals something more serious. Obstructive sleep apnoea is a condition in which a child’s breathing is repeatedly disrupted during sleep. These interruptions can affect growth, behaviour, and learning. Children with this condition may toss and turn at night, struggle to concentrate during the day, or show signs of hyperactivity and fatigue. Traditionally, enlarged tonsils and adenoids have been seen as the main culprits. Surgery to remove them has long been considered the standard treatment. However, research led by Consultant ENT Surgeon Ms. Aikaterini Dritsoula of The Leeds Teaching Hospitals NHS Trust invites us to look deeper. Her work suggests that the story is often more complex, especially in very young children.